Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Intravenous versus oral etoposide : efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Tytuł :
Intravenous versus oral etoposide : efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Autorzy :
Ali, Abir Salwa
Grönberg, Malin
Langer, Seppo W.
Ladekarl, Morten
Hjortland, Geir Olav
Vestermark, Lene Weber
Österlund, Pia
Welin, Staffan
Grønbæk, Henning
Knigge, Ulrich
Sorbye, Halfdan
Janson, Eva Tiensuu
Pokaż więcej
Temat :
Retrospective Studies
Cancer och onkologi
Kaplan-Meier Estimate
CONSENSUS GUIDELINES
Antineoplastic Agents, Phytogenic/administration & dosage
Pancreatic Neoplasms/drug therapy
Biolääketieteet - Biomedicine
Chemotherapy
NEC
Infusions, Intravenous
Neuroendocrine Tumors/drug therapy
Intravenous
CARCINOMAS
CISPLATIN
Female
3122 Cancers
Neuroendocrine neoplasms
PREFERENCES
Stomach Neoplasms/drug therapy
CELL LUNG-CANCER
Aged
DIAGNOSIS
Middle Aged
CLASSIFICATION
Original Paper
Treatment Outcome
Administration, Oral
Cancer and Oncology
TUMORS
WHO G3
Disease-Free Survival
Intestinal Neoplasms/drug therapy
Oral
Etoposide
Journal Article
Etoposide/administration & dosage
Aged, 80 and over
Adult
Syöpätaudit - Cancers
Humans
Male
Proportional Hazards Models
Źródło :
Ali, A S, Grönberg, M, Langer, S W, Ladekarl, M, Hjortland, G O, Vestermark, L W, Österlund, P, Welin, S, Grønbæk, H, Knigge, U, Sorbye, H & Janson, E T 2018, ' Intravenous versus oral etoposide : efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3) ', Medical Oncology, vol. 35, no. 4, 47, pp. 1-7 . https://doi.org/10.1007/s12032-018-1103-x
Ali, A S, Grönberg, M, Langer, S W, Ladekarl, M, Hjortland, G O, Vestermark, L W, Österlund, P, Welin, S, Grønbæk, H, Knigge, U, Sorbye, H & Janson, E T 2018, ' Intravenous versus oral etoposide : efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3) ', Medical Oncology, vol. 35, no. 4, 47 . https://doi.org/10.1007/s12032-018-1103-x
Medical Oncology (Northwood, London, England)
Ali, A S, Grönberg, M, Langer, S W, Ladekarl, M, Hjortland, G O, Vestermark, L W, Österlund, P, Welin, S, Grønbæk, H, Knigge, U, Sorbye, H & Janson, E T 2018, ' Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3) ', Medical Oncology, vol. 35, no. 4, pp. 47 . https://doi.org/10.1007/s12032-018-1103-x
Wydawca :
Haukeland Hosp, Dept Oncol, Bergen, Norway., 2018.
Rok publikacji :
2018
Kolekcja :
Theses_asb
PURE_Aarhus_University
Publikationer_fran_Uppsala_Universitet_enriched
University_of_Southern_Denmark_Research_Output
PURE_Aarhus_University_enriched
Theses_asb_enriched
Publikationer_fran_Uppsala_Universitet
University_of_Southern_Denmark_Research_Output_enriched
Oryginalny identyfikator :
pmc: PMC5840252
pmid: 29511910
Opis pliku :
application/pdf; fulltext
Język :
English
ISSN :
1559-131X
1357-0560
DOI :
10.1007/s12032-018-1103-x
High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter-and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (= 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan-Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies